Enabling Precision Cancer Clinical Trials: A molecular profiling platform for the Australian clinical trials industry
To facilitate genomics testing and patient matching for clinical trials and focussed therapies the Garvan will engage at least 5 companies and have 250 tests conducted on a purpose built SME engagement platform.
This project will deliver a molecular profiling platform to increase capacity in Australia’s clinical trial sector, and increase the attractiveness of Australia to the international pharmaceutical industry. The platform includes a clinically-accredited molecular test for cancer trials, a genomics data platform to support clinical trials, and patient-matching capabilities to facilitate clinical trial recruitment.
Outcomes: This project successfully developed a comprehensive genome profiling platform to enable precision cancer medicine. The platform has been successfully transferred to SydPath enabling sector wide access. The project has held 13 training an information events, promoting the potential of the test to over 450 individuals
| State | New South Wales |
| Consortium lead | The Garvan Institute of Medical Research |
| Consortium members | NHMRC Clinical Trials Centre, NSW Early phase Clinical Trials Alliance (NECTA), Genome.One, Linear Clinical Research |
| MTPConnect grant | $316,256 |
| Industry contribution | $338,820 |
| Project duration | April 2018 - March 2020 |
| Contact | A/Prof Luke Hesson, The Garvan Institute of Medical Research - l.hesson@garvan.org.au |
Visit Garvan Institute of Medical Research's website for more information.
Twitter: GarvanInstitute | LinkedIn: Garvan Institute of Medical Research